Dr. Paz-Ares Discusses the Use of Pemetrexed for NSCLC

Luis Paz-Ares, MD, PhD

Published Online: Friday, June 17, 2011

Print

Email

Luis Paz-Ares, MD, PhD the chair of oncology at Seville University Hospital in Spain discusses the use of pemetrexed in advanced nonsquamous non–small cell lung cancer.

View more videos of Luis Paz-Ares, MD, PhD.

Comment(s)

Your comments are valuable to us. Thank you.

Sorry, you must be logged in and registered to post a comment.

Related Articles

Maintenance Therapy With Bevacizumab/Pemetrexed Appears Superior to Bevacizumab Alone

Maintenance therapy with bevacizumab plus pemetrexed achieved a 4-month benefit in progression-free survival (PFS) versus bevacizumab maintenance therapy alone.

FDA Grants Priority Review to Pfizer's Crizotinib

Crizotinib was accepted for filing by the FDA and granted Priority Review status

MetMAb Plus Erlotinib Improves Survival for Patients With MET-Positive NSCLC

Add-on therapy with an inhibitor of the MET signaling pathway significantly improved PFS and OS in patients with MET-positive NSCLC confirmed by immunohistochemistry.

Most Popular Right Now

New Therapies for Prostate Cancer: The Practicalities

Is There a Best Adjuvant Chemotherapy Regimen for Breast Cancer?

5-alpha Reductase Inhibitors Help Prostate Cancer Patients on Active Surveillance

PCPs Highly Unaware of Long-Term Chemotherapy Side Effects

Sipuleucel-T Stimulates Response in Localized Setting, Study Finds

Bringing the Oncology Community Together

Dr. Paz-Ares Discusses the Use of Pemetrexed for NSCLC